Huntington disease: pathogenesis and treatment.

Huntington disease (HD) is an autosomal dominant inherited neurodegenerative disease characterized by progressive motor, behavioral, and cognitive decline, culminating in death. It is caused by an expanded CAG repeat in the huntingtin gene. Even years before symptoms become overt, mutation carriers show subtle but progressive striatal and cerebral white matter atrophy by volumetric MRI. Although there is currently no direct treatment of HD, management options are available for several symptoms. A better understanding of HD pathogenesis, and more sophisticated clinical trials using newer biomarkers, may lead to meaningful treatments. This article reviews the current knowledge of HD pathogenesis and treatment.

[1]  J. Penney,et al.  Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study , 2004, Journal of Chemical Neuroanatomy.

[2]  A. Young,et al.  Milestones in Huntington disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[3]  K. Marder,et al.  Relationship between CAG repeat length and late-stage outcomes in Huntington’s disease , 2002, Neurology.

[4]  A. Dale,et al.  Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.

[5]  G. Bruyn,et al.  Duration of illness in Huntington's disease is not related to age at onset. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[6]  Chris Frost,et al.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data , 2013, The Lancet Neurology.

[7]  G. Sedvall,et al.  PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.

[8]  Joseph B. Martin,et al.  Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease , 1987, Brain Research.

[9]  D. Housman,et al.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Tsien,et al.  In Vivo Evidence for NMDA Receptor-Mediated Excitotoxicity in a Murine Genetic Model of Huntington Disease , 2009, The Journal of Neuroscience.

[11]  D. Housman,et al.  Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease , 2013, Proceedings of the National Academy of Sciences.

[12]  Paul W Goldberg,et al.  A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. , 1994, The New England journal of medicine.

[13]  T. Bird,et al.  Risk factors for suicide in Huntingtons disease: a retrospective case controlled study. , 1993, American journal of medical genetics.

[14]  J. Jankovic,et al.  Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS , 2013, Neurology.

[15]  Jane S. Paulsen,et al.  Cognitive decline in prodromal Huntington Disease: implications for clinical trials , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  C A Ross,et al.  Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. , 1993, Human molecular genetics.

[17]  D. Falush,et al.  Measurement of mutational flow implies both a high new-mutation rate for Huntington disease and substantial underascertainment of late-onset cases. , 2001, American journal of human genetics.

[18]  K. Marder,et al.  Weight loss in early stage of Huntington’s disease , 2002, Neurology.

[19]  L. Raymond,et al.  Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.

[20]  E. Holzbaur,et al.  The Regulation of Autophagosome Dynamics by Huntingtin and HAP1 Is Disrupted by Expression of Mutant Huntingtin, Leading to Defective Cargo Degradation , 2014, The Journal of Neuroscience.

[21]  Michael R. Hayden,et al.  Mutant Huntingtin Enhances Excitotoxic Cell Death , 2001, Molecular and Cellular Neuroscience.

[22]  M. Gerlach,et al.  The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. , 2004, Journal of neural transmission. Supplementum.

[23]  Aman A. Savani,et al.  Practice Advisory: Utility of surgical decompression for treatment of diabetic neuropathy: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology , 2007, Neurology.

[24]  H. Przuntek,et al.  Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series , 2006, BMC neurology.

[25]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[26]  J. Ferreira,et al.  An evidence-based approach in the treatment of Huntington's disease. , 2012, Parkinsonism & related disorders.

[27]  D. Brooks,et al.  Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease , 1996, Annals of neurology.

[28]  S. Luquet,et al.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. , 2006, Cell metabolism.

[29]  Jane S. Paulsen,et al.  The disparate effects of Alzheimer's disease and Huntington's disease on semantic memory. , 1999, Neuropsychology.

[30]  L. Smeeth,et al.  Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[31]  R. Schiffmann,et al.  Early Alterations of Brain Cellular Energy Homeostasis in Huntington Disease Models* , 2011, The Journal of Biological Chemistry.

[32]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[33]  L. Cif,et al.  Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. , 2008, Journal of neurosurgery.

[34]  J. Penney,et al.  Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.

[35]  M. Nance.  Comprehensive care in Huntington's disease A physician's perspective , 2007, Brain Research Bulletin.

[36]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[37]  J. Caviston,et al.  Huntingtin facilitates dynein/dynactin-mediated vesicle transport , 2007, Proceedings of the National Academy of Sciences.

[38]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[39]  Vincent A Magnotta,et al.  Longitudinal change in regional brain volumes in prodromal Huntington disease , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[40]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[41]  M. Hayden,et al.  The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease , 1993, Nature Genetics.

[42]  M. Hayden,et al.  Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk , 2014, Movement disorders : official journal of the Movement Disorder Society.

[43]  C Michael Stein,et al.  Atypical antipsychotic drugs and the risk of sudden cardiac death. , 2009, The New England journal of medicine.

[44]  A. Orr,et al.  Impaired ubiquitin–proteasome system activity in the synapses of Huntington's disease mice , 2008, The Journal of cell biology.

[45]  M. Hayden,et al.  A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease. , 1999, American journal of human genetics.

[46]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[47]  B Fischl,et al.  Regional cortical thinning in preclinical Huntington disease and its relationship to cognition , 2005, Neurology.

[48]  Jane S. Paulsen,et al.  Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities , 2007, Journal of clinical and experimental neuropsychology.

[49]  Dimitri Krainc,et al.  Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.

[50]  Jane S. Paulsen,et al.  Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. , 2011, Brain : a journal of neurology.

[51]  Jane S. Paulsen,et al.  Neuropsychiatric aspects of Huntington's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[52]  M. de Tommaso,et al.  Two Years' Follow-up of Rivastigmine Treatment in Huntington Disease , 2007, Clinical neuropharmacology.

[53]  A. Graybiel,et al.  Striosomes and mood dysfunction in Huntington's disease. , 2007, Brain : a journal of neurology.

[54]  L. Raymond,et al.  N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease , 2007, Progress in Neurobiology.

[55]  J. Pruim,et al.  Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease , 2005, Neurology.

[56]  J. Caviston,et al.  Huntingtin as an essential integrator of intracellular vesicular trafficking. , 2009, Trends in cell biology.

[57]  M. Hayden,et al.  High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia , 2001, Clinical genetics.

[58]  P. Starr,et al.  Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington's disease , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[59]  P. Hemachandra Reddy,et al.  Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. , 2011, Human molecular genetics.

[60]  J. Olson,et al.  Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.

[61]  C. Ross,et al.  Age, CAG repeat length, and clinical progression in Huntington's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[62]  I. Shoulson,et al.  Psychiatric syndromes in Huntington's disease. , 1983, The American journal of psychiatry.

[63]  S. Finkbeiner,et al.  Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease* , 2010, The Journal of Biological Chemistry.

[64]  Jessica K. Lee,et al.  Measures of growth in children at risk for Huntington disease , 2012, Neurology.

[65]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[66]  A. Reiner,et al.  Striatal parvalbuminergic neurons are lost in Huntington's disease: implications for dystonia , 2013, Movement disorders : official journal of the Movement Disorder Society.

[67]  D. Sulzer,et al.  CARGO RECOGNITION FAILURE IS RESPONSIBLE FOR INEFFICIENT AUTOPHAGY IN HUNTINGTON’S DISEASE , 2010, Nature Neuroscience.

[68]  E. Siemers,et al.  Longitudinal personality changes among presymptomatic Huntington disease gene carriers. , 2002, Neuropsychiatry, neuropsychology, and behavioral neurology.

[69]  J. Penney,et al.  Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity‐akinesia , 1990, Annals of neurology.

[70]  S. Folstein,et al.  Saccades in Huntington's disease , 1987, Neurology.

[71]  L. Raymond,et al.  Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin , 1999, Journal of neurochemistry.

[72]  Jane S. Paulsen,et al.  Psychiatric Symptoms in Huntington’s Disease before Diagnosis: The Predict-HD Study , 2007, Biological Psychiatry.

[73]  B. Rosen,et al.  Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.

[74]  R. Llinás,et al.  Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[75]  P. O'Suilleabhain,et al.  A randomized trial of amantadine in Huntington disease. , 2003, Archives of neurology.

[76]  K. Kieburtz,et al.  Functional decline in Huntington's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.

[77]  J. Jankovic,et al.  Exploring the Correlates of Intermediate CAG Repeats in Huntington Disease , 2011, Postgraduate medicine.

[78]  E. Siemers,et al.  Evaluation of psychological symptoms among presymptomatic HD gene carriers as measured by selected MMPI scales. , 2002, Journal of psychiatric research.

[79]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[80]  M. MacDonald,et al.  Trinucleotide repeat length and progression of illness in Huntington's disease. , 1994, Journal of medical genetics.

[81]  Jane S. Paulsen,et al.  Depression and stages of Huntington's disease. , 2005, The Journal of neuropsychiatry and clinical neurosciences.

[82]  J. Jankovic,et al.  CAG repeat size and clinical presentation in Huntington's disease , 1994, Neurology.

[83]  S E Leurgans,et al.  Effect of donepezil on motor and cognitive function in Huntington disease , 2006, Neurology.

[84]  Mauro Delorenzi,et al.  Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. , 2007, Human molecular genetics.

[85]  Jane S. Paulsen,et al.  Distinct cognitive profiles of cortical and subcortical dementia in advanced illness , 1995, Neurology.

[86]  F. Gabreëls,et al.  Seven cases of huntington's disease in childhood and levodopa induced improvement in the hypokinetic — Rigid form , 1980, Clinical Neurology and Neurosurgery.

[87]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[88]  Howard Schulman,et al.  Global changes to the ubiquitin system in Huntington's disease , 2007, Nature.

[89]  J. Wuu,et al.  Huntington’s disease: A randomized, controlled trial using the NMDA-antagonist amantadine , 2002, Neurology.